Detalhe da pesquisa
1.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534646
2.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31003911
3.
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Oncologist
; 22(9): 1024-e89, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592615
4.
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
J Transl Med
; 15(1): 146, 2017 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28646893
5.
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Obstet Gynecol
; 108(3 Pt 1): 515-20, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16946209
6.
Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy.
Clin Breast Cancer
; 6(4): 354-6, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16277887
7.
Multifocal breast cancer in women < or =35 years old.
Cancer
; 110(7): 1445-50, 2007 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17676585
8.
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Cancer
; 107(12): 2745-51, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17109443